ABOUT KINAXO

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. We are a service company specializing in chemical proteomics methods to support the successful development of small molecule drugs. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, we continuously expand and improve our technology platform in collaboration with the leading Max Planck laboratories of Axel Ullrich, Henrik Daub and Matthias Mann. KINAXO offers its clients extensive experience in cellular target profiling and other chemical proteomics applications.

KINAXO’s chemical proteomics platform was developed and optimized over several years by its founders Dr. Henrik Daub and Dr. Axel Ullrich. Additional founding shareholders are Dr. Hellmut Kirchner, Axel Leimer and Dr. Andreas Jenne, as well as BioM AG and the Max Planck Society.